Manuscripts

 

This section includes a list of publications related to emicizumab and specific topics of interest. The publications included aim to provide scientific, objective and balanced information about emicizumab. You can find the criteria used to collect these lists below*. They will be updated periodically by the Roche scientific team.

Due to copyrights, we can not provide access to all the publications included. If you are unable to access any of these manuscripts via your existing subscriptions, please contact your local Roche medical information department for assistance.

*The first search included all publications with the words 'emicizumab' and 'ACE910'. Due to the aim of this website, the following types of publications were not included:

  • Letter to the editor, Editorials, Commentaries and News.
  • Publications that are not specific about emicizumab.
  • Publications containing off-label information about emicizumab.
  • Publications that use emicizumab in animal models.
Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients.

Ocaña Gómez MÁ, Ferrer Machín A, Vera Cabrera M, et al. Med Clin (Barc) 2023; DOI:10.1016/j.medcli.2023.07.024

Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres

Ranta S, Motwani J, Blatny J, et al. Haemophilia 2023;29(5):1291-1298

Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen.

Okolo A, Shapiro A, Janson I, et al. Haemophilia 2023;29(5):1299-1305

Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey.

Chamouard V, Freyssenge J, Duport G, at al. Haemophilia 2023;29(6):1490-1498

Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.

Shimonishi N, Sasai K, Ogiwara K, et al. Int J Hematol 2023;118(6):690-698

Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.

Shen MC, Chou SC, Chiou SS, et al. Haemophilia 2023;29(6):1499-1508

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center.

Cohen O, Levy-Mendelovich S, Budnik I, et al. Res Pract Thromb Haemost 2023;7(6):102178

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience.

Rener K, Anžej Doma S, Fink M, et al. Hematol Rep 2023;15(4):597-607

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience

Castaman G, Linari S, Pieri L, et al. J Clin Med. 2023;12(6):2317

Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature.

Kizilocak H, Guerrera MF, Young G. Res Pract Thromb Haemost 2023;7(6):102194

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes

Levy-Mendelovich S, Atia N, Budnik I, et al. Res Pract Thromb Haemost. 2023;7(4):100278

Expert opinion paper on the treatment of hemophilia A with emicizumab.

López-Jaime FJ, Benítez O, Díaz Jordán BL, et al. Hematology 2023;28(1):2166334

Blue toe syndrome, severe haemophilia A and emicizumab

Cardoso PSR, da Silva CBPG, de Abreu ES, et al. Haemophilia 2023; https://doi.org/10.1111/hae.14893

Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab

Atsou S, Schellenberg C, Lagrange J, et al. J Thromb Haemost 2023;S1538-7836(23)00719-5. doi: 10.1016/j.jtha.2023.09.017

Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort.

Batsuli G, Wheeler AP, Weyand AC, Sidonio Jr, Young G. Am J Hematol. 2023; published online ahead of print

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis

Garcia J, Hammer MR, Zia A. Res Pract Thromb Haemost 2023;7(8):102238

The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.

Onishi T, Harada S, Shimo H, et al. Haemophilia 2023;29(6):1529-1538

A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors

Escobar M, Bullano M, Mokdad AG, et al. Expert Rev Hematol. 2023;16(6):467-474

Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation

Awane M, Wakui M, Ozaki Y, et al. Clin Chim Acta. 2023;544:117339

Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A

Takeyama M, Matsumoto N, Abe H, et al. Pediatr Blood Cancer. 2023;70(10):e30590

Cholecystectomy in a man with hemophilia A and inhibitor on emicizumab prophylaxis: A case report.

Giacometto PC, Bavaresco MT, Alvares-Teodoro J, Camelo RM. Hematol Transfus Cell Ther. 2023; published online ahead of print

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.

Matsumoto N, Abe H, Kawasaki R, et al. TH Open 2023;7(3):e241-e243

Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO)

Wall C, Xiang H, Palmer B, et al. Haemophilia. 2023;29(3):743-752

Management of children with hemophilia A on emicizumab who need surgery

Belletrutti M, Bhatt M, Samji N. Front Pediatr. 2023;11:1155853

Functional determination of emicizumab in presence of factor VIII activity

Hamedani NS, Donners AAMT, van Luin M, et al. J Thromb Haemost 2023;21(12):3490-3500

Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast

Lambert C, Meité N, Kouassi GK, et al. Res Pract Thromb Haemost. 2023;7(1):100033

Between Scylla and Charybdis: thrombosis in children with hemophilia

El Maamari J, Amid A, Pelland-Marcotte MC, Tole S. Front Pediatr. 2023;11:1173549

Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis.

Furukawa S, Ogiwara K, Yada K, et al. Blood Coagul Fibrinolysis. 2023;34(2):122-128

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.

Valls R, Wagg J, Paz-Priel I, et al. Sci Reports. 2023;13(1):10078

Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A

Bertaggia Calderara D, Marchi Cappelletti R, Batista Mesquita Sauvage AP, et al. Thromb Haemost. 2023; published online ahead of print

Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy.

Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Haemophilia. 2023; 29(3):709-715

Hemophilia A: Emicizumab monitoring and impact on coagulation testing.

Nardi MA. Adv Clin Chem. 2023;113:273-315

Successful in-patient management of COVID-19 infection in an old severe haemophilia A patient on emicizumab with multiple prothrombotic comorbidities.

Houssiau H, Hermans C. Haemophilia. 2023;29(2):674-675

Clinical pharmacology of emicizumab for the treatment of hemophilia A

Yoneyama K, Schmitt C, Portron A, et al. Expert Rev Clin Pharmacol. 2023; published online ahead of print

Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.

Wei L, Tian Y, Chen X, et al. Int J Clin Pharm. 2023;45:622–629

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.

Négrier C, Mahlangu J, Lehle M, et al. Lancet Haematol. 2023;10(3):e168-e177

In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.

Yamaguchi T, Shinozawa K, Nagatoishi S, et al. Thromb Res. 2023;222:131-139

A Retrospective Analysis of the American Thrombosis and Hemostasis Network Dataset Describing Outcomes of Dental Extractions in Persons with Hemophilia

Messenger H, Kulkarni R, Recht M, He C. J Clin Med. 2023;12(5):1839

Hemophilia treatment innovation: 50 years of progress and more to come.

Mannucci PM. J Thromb Haemost. 2023;21(3):403-412

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report.

Albattat S, Alabdultaif A, Albattat F, Albattat B. J Med Case Rep. 2023;17(1):63

Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021

Maria A, Alessandro C, Declan N, Peyvandi F. J Thromb Haemost. 2023;21(3):546-552

Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab.

Mak S, Marszal A, Matscheko N, Rant U. MAbs. 2023;15(1):2149053

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.

Pipe SW, Trzaskoma B, Minhas M, et al. Res Pract Thromb Haemost. 2023;7(2):100077

The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?

Bowyer AE, Maclean RM, Kitchen S. Int J Lab Hematol. 2023;45(3):368-376

From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A.

Mihaila RG. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023;167(1):1-8

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage

Yamada Y, Nakajima Y, Ohara A, et al. Int J Hematol. 2023;117:607-612

Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A.

Mahajerin A, Faghmous I, Kuebler P, et al. J Comp Eff Res. 2022;11(10):717-728

Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY)

Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Res Pract Thromb Haemost. 2022;6(8):e12837

The Implication of New Developments in Hemophilia Treatment on Its Laboratory Evaluation

Anandani G, Patel T, Parmar R. Cureus 2022;14(10):e30212

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

Liu G, Huang K, Li G, et al. Front Pediatr. 2022;10:992267

Immunogenicity of Current and New Therapies for Hemophilia A

Prezotti ANL, Frade-Guanaes JO, Yamaguti-Hayakawa GG, Ozelo MC. Pharmaceuticals (Basel). 2022;15(8):911

Emicizumab-induced photosensitivity

Asensi Cantó P, Rodríguez Serna M, Lloret Madrid P, TH Open. 2022;6(3):e154-e155.

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.

Matsushita T, Suzuki N, Nagao A, et al. BMJ Open. 2022 Mar 14;12(3):e057018

A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A

Yoneyama K, Schmitt C, Chang T, et al. J Clin Pharmacol. 2022 Feb;62(2):232-244.

Safety of intramuscular COVID-19 vaccination in patients with haemophilia

Tiede A, Leise H, Horneff S, et al. Haemophilia. 2022; 28(5):687-693

Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.

Takeyama M, Furukawa S, Onishi T, et al. Pediatr Blood Cancer. 2022 Apr 20:e29731

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Kiialainen A, Niggli M, Kempton CL, et al. Haemophilia. 2022;28(6):1033-1043

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Blood Adv. 2022;6(24):6140–6150

Development of simple and rapid method for emicizumab quantification by LC-MS/MS in human plasma

Josset L, Hodin S, Delinger S, et al. J Pharm Biomed Anal. 2023;223:115163

Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A

Sun SX, Frick A, Balasa V, Roberts JC. Expert Rev Hematol. 2022;15(10):943-950

Emicizumab in children: bleeding episodes and outcome before and after transition to emicizumab

Glonnegger H, Andresen F, Kapp F, et al. BMC Pediatr. 2022;22(1):487

Advances in Hemophilia A Management.

Cho S, Perry AM, Cheng AM, Wang C, Rico JF. Adv Pediatr. 2022;69(1):133-147

Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab: a case report.

Kawahara F, Shirayama R, Ito T, et al. Int J Hematol. 2022;115:906–912

AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study

Shima M, Takedani H, Kitsukawa K, et al. BMJ Open. 2022;12(6):e059667

Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.

Nakajima Y, Mizumachi K, Shimonishi N, et al. Int J Hematol. 2022 Apr;115(4):489-498

A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.

Escobar M, Dunn A, Quon D, et al. Haemophilia. 2022; 28(4):e105-e108

Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).

Yang R, Wang S, Wang X, et al. Res Pract Thromb Haemost. 2022 Mar 7;6(2):e12670

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

Donners AAMT, Gerencsér L, van der Elst KCM, et al. Res Pract Thromb Haemost. 2022;6(4):e12725

Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels

Hamedani NS, Oldenburg J, Pötzsch B, Müller J. PLoS One. 2022;17(7):e0271330

Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review.

Hassan E, Motwani J. Pediatr Hematol Oncol. 2022 Feb 16:1-9

Current and future therapies for haemophilia-Beyond factor replacement therapies.

Nogami K, Shima M. Br J Haematol. 2023;200(1):23-34

The More Recent History of Hemophilia Treatment.

Franchini M, Mannucci PM. Semin Thromb Hemost. 2022;48(8):904-910

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab.

Inoue F, Terada K, Furudate K, et al. Hematol Rep. 2022 Mar 30;14(2):108-111

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.

Ogiwara K, Taki M, Suzuki T, et al. BMJ Open. 2022 Feb 17;12(2):e056922

Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement

Kershaw G, Dix C, Chen VM, Cai N, Khoo TL. Pathology. 2022;54(6):P755-762

Monitoring of new therapies for hemophilia.

Fernandez-Bello I. Blood Coagul Fibrinolysis. 2022 Jan 1;33(Suppl 1):S3-S4

Non-factor therapies for bleeding disorders: A primer for the general haematologist.

Swan D, Mahlangu J, Thachil J. EJHaem. 2022;3(3):584-595

Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab

Isaacs J, Welsby IJ, Schroder JN, Onwuemene OA. J Cardiothorac Vasc Anesth. 2021 Nov;35(11):3299-3302.

Emicizumab does not interfere with the activated clotting time.

Capdevila L, Frère C, Desvages M, et al. Haemophilia. 2022 Mar;28(2):362-366

An update of the current pharmacotherapeutic armamentarium for hemophilia A.

Mahlangu J. Expert Opin Pharmacother. 2022 Jan;23(1):129-138

Emicizumab treatment in chronic intermittent haemodialysis

Weise M, Siegemund A, Böhme L, et al. Haemophilia. 2022 Jan;28(1):e20-e22.

Emicizumab for All Pediatric Patients with Severe Hemophilia A.

Wieland I. Hamostaseologie. 2022 Apr;42(2):104-115

Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report

Guillaume L, van Dievoet MA, Lambert C, Hermans C. Ther Adv Hematol. 2021;12:doi:10.1177/20406207211040345

Emicizumab state-of-the-art update.

Mahlangu J, Iorio A, Kenet G. Haemophilia. 2022 May;28 Suppl 4:103-110

Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A

Kaneda M, Kawasaki R, Matsumoto N, et al. J Thromb Haemost. 2021 Dec;19(12):2938-2946.

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes

Camelo RM, de Medeiros TC, de Albuquerque DGB, Álvares-Teodoro J. Hematol Transfus Cell Ther. 2023:45(1):98-101

Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making

Mason JA, Young G. Haemophilia. 2021 Sep;27(5):724-729

Severe bleeding after haemorrhoidal banding in a haemophilia patient treated with emicizumab

Barish J, Hajdenberg J. Haemophilia. 2021 Jul;27(4):e589-e590

Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?

Holstein K, Le Quellec S, Klamroth R, et al. Haemophilia. 2022 Mar;28(2):215-222.

Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors

Hassan E, Jonathan L, Jayashree M. Haemophilia. 2021 Nov;27(6):e698-e703.

In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients

Tanaka KA, Henderson R, Thangaraju K, et al. Haemophilia. 2022 Jan;28(1):183-190.

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Parnes A, Mahlangu JN, Pipe SW, et al. Haemophilia. 2021 Nov;27(6):e772-e775.

The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me

Fletcher S, Jenner K, Holland M, Khair K. Health Expect. 2022 Feb;25(1):443-454.

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient

Harroche A, Sefiane T, Desvages M, et al. Haematologica. 2021 Aug 1;106(8):2287-2290

Low immunogenicity of emicizumab in persons with haemophilia A

Schmitt C, Emrich T, Chebon S, et al. Haemophilia. 2021 Nov;27(6):984-992

Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature

Swan D, Paran S, Nolan B. Haemophilia. 2022 Jan;28(1):42-45.

Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study

Cohen CT, Diaz R. Pediatr Blood Cancer. 2021 Nov;68(11):e29325.

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor

Lefèvre CR, Jaffré A, Pontis A, et al. TH Open. 2021 May 12;5(2):e163-e165

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab

Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. J Clin Med. 2021;10(19):4303

Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy

Capdevila L, Borgel D, Lasne D, et al. Haemophilia. 2021 Jul;27(4):e581-e584

Benefits of prophylactic emicizumab in enhancing immune tolerance induction in a boy with hemophilia A and very high inhibitor titer

Sirachainan N, Chuansumrit A, Parapakpenjune S, et al. Pediatr Blood Cancer. 2021 Sep;68(9):e29111

Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit

Urbaniak-Kujda D, Biernat MM, Skalec T, et al. Haemophilia. 2021 Jul;27(4):e567-e570

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report

Warren BB, Chan A, Manco-Johnson M, Branchford BR, et al. Res Pract Thromb Haemost. 2021 Aug 3;5(5):e12571

Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile

Abarca-Villaseca V, Soto-Arellano V. Am J Case Rep. 2021 Apr 22;22:e929598

Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

Doshi BS, Witmer CM. Haemophilia. 2021 Jul;27(4):e551-e553

Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review

Villarreal-Martínez L, Sepúlveda-Orozco MDC, García-Viera DA, et al. Blood Coagul Fibrinolysis. 32(6):418-422, September 2021.

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.

Hatayama Y, Motokura T, Hosoda Y, et al. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221082992

Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors

Lockhart M, Tardy-Poncet B, Montmartin A, et al. Pediatr Blood Cancer. 2021 Jul;68(7):e29041

Successful emicizumab prophylaxis during dual antiplatelet therapy for insertion of drug-eluting stents after acute coronary syndrome: A case report

Nagao A, Koganei H, Yamaguchi T, Fukutake K. Haemophilia. 2021 Jul;27(4):e549-e550

The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study

Schultz NH, Glosli H, Bjørnsen S, Holme PA. Res Pract Thromb Haemost. 2021 Jun 27;5(5):e12561

Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

Krumb E, Fijnvandraat K, Makris M, et al. [published online ahead of print Jun 30]. Haemophilia. 2021 Jun 30. doi: 10.1111/hae.14372

Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab

Teo HKW, Wong WH, Lam JCM. Haemophilia. 2021 May;27(3):e415-e418.

The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Skinner MW, Négrier C, Paz-Priel I, et al. [published online ahead of print Jun 25]. Haemophilia. 2021 Jun 25. doi: 10.1111/hae.14363

Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays

Kizilocak H, Marquez-Casas E, Malvar J, et al. [published online ahead of print Jun 11]. Haemophilia. 2021 Jun 11. doi: 10.1111/hae.14359

Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK

Hassan E, Motwani J. [published online ahead of print Jun 12]. Haemophilia. 2021 Jun 12. doi: 10.1111/hae.14358

Bispecific antibodies for the treatment of hemophilia A

Shima M. Expert Opin Biol Ther. 2021 Jun 17:1-14

Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis

Mizumachi K, Tsumura Y, Nakajima Y et al. Int J Hematol. 2021 Jun;113(6):930-935.

What proceduralists need to know about emicizumab for patients with hemophilia A

Pivalizza EG, Escobar M. Proc (Bayl Univ Med Cent). 2020 Dec 14;34(2):334-335

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies (Erratum now published)

Callaghan MU, Negrier CG, Paz-Priel I. Blood. 2021 Apr 22;137(16):2231-2242.

Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays

Bowyer A, Kitchen S, Maclean R. Int J Lab Hematol. 2021 Aug;43(4):O204-O206.

Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring

Barg AA, Budnik I, Avishai E, et al. Haemophilia. 2021 May;27(3):383-391

Disruptive technology and hemophilia care: The multiple impacts of emicizumab

Hermans C, Makris M. Res Pract Thromb Haemost. 2021 May 7;5(4):e12508

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report

Ahn JH, Jung N, Shim YJ, Kim HS. Blood Res. 2021 Mar 31;56(1):44-46.

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review

Donners AAMT, Rademaker CMA, Bevers LAH, et al. [published online ahead of print, 2021 Aug 13] Clin Pharmacokinet. 2021 Aug 13. doi: 10.1007/s40262-021-01042-w

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A

Wang CP, Young G, Thornburg CD. Expert Opin Drug Saf. 2021 Apr;20(4):387-396.

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Kempton C, Trask P, Parnes A et al. Haemophilia. 2021 Mar;27(2):221-228.

Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor

Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Int J Hematol. 2021 Jun;113(6):789-796

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data

Misgav M, Brutman-Barazani T, Budnik I, et al. Haemophilia. 2021 Mar;27(2):253-260.

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Haemophilia. 2021 Jul;27(4):519-530

Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor

Valsecchi C, Gobbi M, Beeg M et al. J Thromb Haemost. 2021 Mar;19(3):711-718.

Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

Jonsson F, Schmitt C, Petry C. Clin Pharmacokinet. 2021 Jul;60(7):931-941

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Peyvandi F, Mahlangu JN, Pipe SW et al. J Thromb Haemost. 2021;19(Suppl. 1):32-41.

Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway

Szanto T, Vaide I, Jouppila A, et al. Haemophilia. 2021 Jul;27(4):e571-e574

Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Shima M, Nagao A, Taki M, et al. Haemophilia. 2021 Jan;27(1):81-89.

Approximation of emicizumab plasma levels in emergency situations. A practical approach

Pekrul I, Pfrepper C, Calatzis G et al. Haemophilia. 2021 Mar;27(2):e214-e220.

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Batsuli G, Greene A, Meeks SL, Sidonio RF. Res Pract Thromb Haemost. 2021 Feb 8;5(2):342-348

Management of children with hemophilia A: How emicizumab has changed the landscape

Young G. J Thromb Haemost. 2021 Jul;19(7):1629-1637.

Emicizumab therapy in a haemophilia patient with previous pulmonary embolism

Holzmann J, Coulsen H, Poulsen W et al. Paediatr Child Health. 2020 Dec;56(12):2001-2002.

Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study

Yu JK, Iorio A, Chelle P, Edginton AN. Haemophilia. 2021 May;27(3):358-365

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

Pipe SW, Kruse-Jarres R, Mahlangu JN et al. J Thromb Haemost. 2021;19(Suppl. 1):21–31.

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma

Grandoni J, Duretz V, Bonzo D et al. Haemophilia. 2021 Mar;27(2):321-328.

Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL)

von Mackensen S, Catalani O, Asikanius E, et al. Haemophilia. 2020 Nov;26(6):1019-1030.

Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab

Miller CH, Boylan B, Payne AB et al. Int J Lab Hematol. 2021 Apr;43(2):e84-e86.

Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab

Garcia J, Zia A. Pediatr Blood Cancer. 2021 May;68(5):e28942.

Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors

Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. [published online ahead of print, 2021 Jan 27] Expert Rev Hematol. 2021 Jan 27:1-6. doi: 10.1080/17474086.2021.1875817.

Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child

Chehade H, Cachat F, Beck-Popovic M, et al. Pediatrics. 2020 Nov;146(5):e20200123.

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Schmitt C, Adamkewicz JI, Xu J, et al. Thromb Haemost. 2021 Mar;121(3):351-360

Mortality in congenital hemophilia A – A systematic literature review

Hay CRM, Nissen F, Pipe SW. J Thromb Haemost. 2021;19(Suppl. 1):6-20.

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

Kizilocak H, Marquez-Casas E, Phei Wee C, et al. Haemophilia. 2021 Jan;27(1):164-172.

Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study

Mancuso ME, Mahlangu J, Sidonio R Jr, et al.  Haemophilia. 2020 Nov;26(6):1009-1018.

Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise

Lowe A, Kitchen S, Jennings I, et al. Haemophilia. 2020 Nov;26(6):1087-1091.

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US

Lewandowska M, Randall N, Bakeer N, et al. Haemophilia. 2021 Jan;27(1):90-99.

Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

Escuriola-Ettingshausen C, Auerswald G, Königs C, et al.  Haemophilia. 2021 May;27(3):e305-e313

Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor

Chen YW, Chen WJ, Tseng MS, et al. Haemophilia. 2021 May;27(3):e385-e388

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Yoneyama K, Schmitt C, Kotani N, et al. Clin Pharmacokinet 2018;57:1123–1134.

Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis

Batsuli G, Zimowski KL, Tickle K, et al. Haemophilia 2019;25:789–796.    

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

Retout S, Schmitt C, Petry C, Mercier F, Frey N. [published online ahead of print, 2020 Jun 5]. Clin Pharmacokinet. 2020;10.1007/s40262-020-00904-z.

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Sampei Z, Igawa T, Soeda T, et al. PLoS One 2013;8:e57479.

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro.

Noguchi-Sasaki M, Soeda T, Ueyama A, et al. TH Open 2018;2:e96–e103.    

Concomitant Use of rFVIIa and Emicizumab in People With Hemophilia A With Inhibitors: Current Perspectives and Emerging Clinical Evidence

Linari S and Castaman G. Ther Clin Risk Manag 2020;16:461–469.

A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X

Ogiwara K, Nogami K, Matsumoto N, et al. [published online ahead of print, 2020 Aug 3]. Int J Hematol. 2020;10.1007/s12185-020-02959-x.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

Oldenburg J, Shima M, Kruse-Jarres R, et al. [published online ahead of print, 2020 Aug 9]. Pediatr Blood Cancer. 2020;e28474.

Emicizumab treatment: Impact on coagulation tests

Nougier C, Jeanpierre E, Ternisien C, et al. [published online ahead of print, 2020 Jul 15]. Eur J Haematol. 2020;10.1111/ejh.13490.

Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

Barg AA, Livnat T, Budnik I, et al. [published online ahead of print, 2020 Jul 12]. Br J Haematol. 2020;10.1111/bjh.16964.

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. [published online ahead of print, 2020 Jul 27]. Thromb Haemost. 2020;10.1055/s-0040-1714279.

Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study

Khoo L, Matthews S, Kershaw G, et al. Haemophilia. 2020 Nov;26(6):e340-e342

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

Shima M, Hanabusa H, Taki M, et al. N Engl J Med 2016;374:2044–53.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. Haemophilia. 2019;25(4):676-684.

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects

Li H, Zhang W, Petry C, et al. Clin Pharmacol Drug Dev. 2021 Jan;10(1):30-38

Anti-factor IXa/X Bispecific Antibody (ACE910): Hemostatic Potency Against Ongoing Bleeds in a Hemophilia A Model and the Possibility of Routine Supplementation.

Muto A, Yoshihashi K, Takeda M, et al. J Thromb Haemost 2014;12:206–213.

Spotlight on Emicizumab in the Management of Hemophilia A: Patient Selection and Special Considerations

Yada K and Nogami K. J Blood Med 2019;10:171–181.

Non‐additive effect on thrombin generation when a plasma‐derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro

Bravo MI, Raventós A, Pérez A, Costa M, Willis T. J Thromb Haemost. 2020;18(8):1934-1939.

A Multicenter, Open-Label Phase 3 Study of Emicizumab Prophylaxis in Children With Hemophilia A With Inhibitors

Young G, Liesner R, Chang T, et al. Blood 2019;134:2127–2138.

Laboratory issues in gene therapy and emicizumab

Bowyer AE, Lowe AE, Tiefenbacher S. Haemophilia. 2021 Feb;27 Suppl 3:142-147

Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

McCary I, Guelcher C, Kuhn J, et al. Haemophilia. 2020;26(4):631-636.

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia

Shima M. Res Pract Thromb Haemost. 2020;4(4):446-454.

Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation

Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. J Thromb Haemost. 2020 Sep;18(9):2205-2208

Emicizumab should be prescribed independent of immune tolerance induction

Le Quellec S, Negrier C. Blood Adv. 2018;2(20):2783-2786.

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program

Levy GG, Asikanius E, Kuebler P, et al. J Thromb Haemost 2019;17:1470–1477.

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors

Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Br J Haematol. 2020 Sep;190(5):727-735

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

Shima M, Nogami K, Nagami S, et al. Haemophilia. 2019;25(6):979-987.

Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A

Lippi G, Favaloro EJ. Adv Clin Chem. 2019;88:151-167.

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Ebbert PT, Xavier F, Seaman CD, et al. Haemophilia 2020;26:41-46. DOI: 10.1111/hae.13877.

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Le Quellec S. Drug Des Devel Ther. 2020;14:469-481

Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment

Valke LLFG, Beckers EAM, Blijlevens NMA, van Heerde WL, Schols SEM. Haemophilia. 2020 Nov;26(6):e327-e330

Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons With Hemophilia A.

Retout S, Schmitt C, Petry C, et al. Clin Pharmacokinet 2020;doi: 10.1007/s40262-020-00904-z (epub ahead of print).

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Young G. Blood Adv. 2018;2(20):2780-2782.

Factor VIIIa-mimetic Cofactor Activity of a Bispecific Antibody to Factors IX/IXa and X/Xa, Emicizumab, Depends on Its Ability to Bridge the Antigens.

Kitazawa T, Esaki K, Tachibana T, et al. Thromb Haemost 2017;117:1348–1357.

Evaluating the safety of emicizumab in patients with hemophilia A

Langer AL, Etra A, Aledort L. Expert Opin Drug Saf. 2018;17(12):1233-1237.

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII‐deficient plasma, similar to the addition of factor VIII

Shimonishi N, Nogami K, Ogiwara K, et al. Haemophilia. 2020;26(3):e97-e105.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Pipe SW, Shima M, Lehle M, et al. Lancet Haematol 2019;6:e295–e305.

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

Yada K, Nogami K, Ogiwara K, et al. Int J Hematol 2019;110:419–430.    

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort

Barg AA, Avishai E, Budnik I, et al. Pediatr Blood Cancer 2019;66(11):e27886. DOI: 10.1002/pbc.27886.

Emicizumab: A Review in Haemophilia A

Blair, H.A. Drugs 79, 1697–1707 (2019).

First report of emicizumab use in a female patient with severe hemophilia A

Verstraete G, Lambert C, Hermans C. Blood Adv. 2020;4(13):2950-2952.

Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban

Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F. J Thromb Thrombolysis. 2020;49(3):413-419.

The Effect of Emicizumab Prophylaxis on Health-Related Outcomes in Persons With Haemophilia A With Inhibitors: HAVEN 1 Study

Oldenburg J, Mahlangu J, Bujan W, et al. Haemophilia 2019;25:33–44.

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Adamkewicz JI, Chen DC, Paz-Priel I. Thromb Haemost. 2019;119(7):1084-1093.

Emicizumab for the prevention of bleeds in hemophilia A

Mahlangu J. Expert Opin Biol Ther. 2019;19(8):753-761.

Thromboprophylaxis in a patient with COVID‐19 and severe hemophilia A on emicizumab prophylaxis

Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, Martín Salces M, García-Barcenilla S, Jiménez-Yuste V. J Thromb Haemost. 2020 Sep;18(9):2202-2204

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol 2018;183:257–266.

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol 2018;183:257–266.

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro

Minami H, Nogami K, Yada K, et al. J Thromb Haemost. 2019;17(1):126-137.

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Kotani N, Yoneyama K, Kawakami N, et al. Clin Pharmacol Drug Dev 2019;8:702–712.

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A

Müller J, Pekrul I, Pötzsch B, et al. Thromb Haemost 2019;119:1384–1393.

Emicizumab for the treatment of haemophilia A: a narrative review

Franchini M, Marano G, Pati I, et al. Blood Transfus. 2019;17(3):223-228.

A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement

Hooimeijer HL, Lukens MV, Verhagen MV, Meijer K, Stein-Wit MA, Tamminga RYJ. Haemophilia. 2020;26(3):e138-e140.

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.

Minami H, Nogami K, Yada K, et al. J Thromb Haemost 2019;17:126–137.

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol. 2018;183(2):257-266.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A Without Inhibitors

Mahlangu J, Oldenburg J, Paz-Priel I, et al. N Engl J Med 2018;379:811–822.

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies

Nogami K, Soeda T, Matsumoto T, et al. J Thromb Haemost 2018;16:1383–1390.    

Emicizumab for hemophilia A without inhibitors

Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Expert Rev Hematol. 2019;12(7):515-524.

Total knee replacement with and without emicizumab: a unique comparison of perioperative management

Evans MS, Davis C, Eyster ME. Blood Adv. 2020;4(5):855-857.

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Shima M, Nogami K, Nagami S, et al. Haemophilia 2019;25:979–987.

Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

Nakajima Y, Nogami K, Yada K, et al. Thromb Haemost 2020;120:968–976.

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

Noguchi-Sasaki M, Soeda T, Ueyama A, et al. TH Open. 2018;2(1):e96-e103.

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Shima M, Hanabusa H, Taki M, et al. Blood Adv 2017;1:1891–1899.

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab

Nogami K, Matsumoto T, Tabuchi Y, et al. J Thromb Haemost 2018;16:1078–1088.

Emicizumab: Review of the literature and critical appraisal

Rodriguez-Merchan EC, Valentino LA. Haemophilia. 2019;25(1):11-20.

Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring

Biron-Andreani C, Diaz-Cau I, Ranc A, et al. Br J Haematol. 2020;189(3):e100-e103.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Kitazawa T and Shima M. Int J Hematol 2020;111:20–30.

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A

Yoneyama K, Schmitt C, Kotani N, et al. Clin Pharmacokinet. 2018;57(9):1123-1134.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Oldenburg J, Mahlangu JN, Kim B, et al. N Engl J Med 2017;377:809–818.

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

Mahlangu JN. BioDrugs. 2018;32(6):561-570.

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors

Okamoto S, Suzuki N, Suzuki A, et al. TH Open. 2019;3(4):e364-e366.

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.

Shimonishi N, Nogami K, Ogiwara K, et al. Haemophilia 2020;26:e97–e105.

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Kitazawa T, Esaki K, Tachibana T, et al. Thromb Haemost. 2017;117(7):1348-1357.

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Shima M, Hanabusa H, Taki M, et al. N Engl J Med. 2016;374(21):2044-2053.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

Kitazawa T, Shima M. Int J Hematol. 2020;111:20–30.

ST‐Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

Gundabolu K, Goldsweig A, Bhatt VR, Koepsell SA, Harper JL. Haemophilia. 2020;26(1):e5-e8.

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

Sampei Z, Igawa T, Soeda T, et al. MAbs. 2015;7(1):120-128.

A First-In-Human Phase 1 Study of ACE910, a Novel Factor VIII-mimetic Bispecific Antibody, in Healthy Subjects

Uchida N, Sambe T, Yoneyama K, et al. Blood 2016;127:1633–41.

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A

Knight T, Callaghan MU. Therap Adv Hem. 2018;(Oct), 319–34.

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Haematologica. 2019;104(8):e380-e382.

Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays.

Peyvandi F, Kenet G, Pekrul I, et al. J Thromb Haemost 2020;18:1242–1255.

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

Sampei Z, Igawa T, Soeda T, et al. PLoS One. 2013;8(2):e57479.

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A

Díaz-Ricart M, Isola IM, Escolar G. Drugs Today (Barc). 2018;54(10):591-600.

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays

Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. Ther Adv Hematol. 2019;10:2040620719860025.

Emicizumab for hemophilia A with factor VIII inhibitors

Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Expert Rev Hematol. 2018;11(11):835-846.

Emicizumab use in major orthopedic surgery

Seaman CD, Ragni MV. Blood Adv. 2019;3(11):1722-1724.

Emicizumab-kxwh: First Global Approval

Scott LJ, Kim ES. Drugs. 2018;78(2):269-274.

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra‐atrial thrombosis in severe haemophilia with an inhibitor

Weyand AC, Dorfman AL, Shavit JA, Pipe SW. Haemophilia. 2019;25(3):e203-e205.

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Lenting PJ, Denis CV, Christophe OD. Blood. 2017;130(23): 2463–2468.

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Haematologica. 2018;103(4):e181-e183.

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.

Furukawa S, Nogami K, Shimonishi N, et al. Br J Haematol 2020; DOI: 10.1111/bjh.16574 (ePub ahead of print).

A new era of treatment for patients with haemophilia A?

Klamroth R. Hamostaseologie. 2017;37(3):216-218.

Bispecific antibody mimicking factor VIII

Nogami K. Thromb Research. 2016; 141:supp 2, S34-35.

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.

Adamkewicz JI, Chen DC and Paz-Priel I. Thromb Haemost 2019;119:1084–1093.

Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.

Sampei Z, Igawa T, Soeda T, et al. MAbs 2015;7:120–8.